Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer.

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The company garnered $15.8 billion in revenue and adjusted earnings of $2.07 per share, compared to our estimates of $15.2 billion and $1.97, respectively.

Is Merck Stock Fully Valued At $130?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults.

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults

Earnings and revenue surpassed analysts' expectations, indicating a solid quarter. Significant growth in flagship products Keytruda and Gardasil helped drive results.

Merck Shines in Q1 2024 Earnings Surge

Caterpillar

Dow Jones Industrial Average (DJI) components Caterpillar Inc. (NYSE:CAT) and Merck & Co Inc (NYSE:MRK) are moving in opposite directions today after their respective first-quarter earnings reports, as the  blue-chip index eyes its worst single-day decline since March 2023.

Dow Earnings: How Merck, Caterpillar Shares Are Faring

Merck & Co., Inc. (NYSE:MRK ) Q1 2024 Results Conference Call April 25, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Terence Flynn - Morgan Stanley Evan Seigerman - BMO Capital Markets Chris Shibutani - Goldman Sachs Dana Graybosch - Leerink Partners James Shin - Deutsche Bank Umer Raffat - Evercore Tim Anderson - Wolfe Research Louise Chen - Cantor Fitzgerald Trung Huynh - UBS Carter Gould - Barclays Chris Schott - JPMorgan Luisa Hector - Berenberg Seamus Fernandez - Guggenheim Operator Thank you for standing by. Welcome to the Merck & Co. Q1 Sales and Earnings Conference Call [Operator Instructions].

Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript

Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024.

Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

Merck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported better-than-expected quarterly results, and raised and narrowed its guidance on strong sales of its blockbuster cancer-fighting treatments.

Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Results

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Bristol-Myers

Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda helped it post a profit and sales beat. Revenues during the group's first quarter reached US$15.78 billion, topping analysts' expectations of US$15.2 billion.

Merck jumps on profit beat as Bristol Myers Squibb slips to a loss

Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.

Merck raises 2024 profit forecast on strong cancer, HPV drugs sales

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.

Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

Merck & Co. Inc. on Thursday reported first-quarter results that beat analysts' expectations amid strong sales of vaccines and cancer drug Keytruda.

Merck's first-quarter results beat expectations amid healthy vaccine-sales growth

Merck stock could pop Thursday after the drugmaker topped Wall Street's first-quarter expectations and raised its outlook for the year.

Merck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds Persist

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces First-Quarter 2024 Financial Results.

Merck Announces First-Quarter 2024 Financial Results

AbbVie

Amgen

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

Eli Lilly

Pfizer

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

Novo Nordisk

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Gilead Sciences

Sanofi

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates.

Higher Keytruda Sales To Drive Merck's Q1?

Lockheed Martin

Newmont Mining

As an investor with significant positions in equities, I am an optimist. However, it's important to be realistic at the same time.

Investor Alert: Prepare for the Market Crash With These 3 Stocks

AstraZeneca

Big money tends to flow from one sector to the other. During the pandemic, sectors like pharmaceutical and e-commerce were hot.

3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS

Tesla

CNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.

Cramer's week ahead: Earnings from Tesla, Merck and Big Tech

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Merck Stock (MRK)